Zobrazeno 1 - 10
of 263
pro vyhledávání: ''
Autor:
Pieter Steenhuis, Thi Dinh La, Zhanna Gurenko, Hsin Ya Yang, Roslyn Rivkah Isseroff, Aaron M. Glucksman
Publikováno v:
PLoS ONE
PloS one, vol 16, iss 7
PLoS ONE, Vol 16, Iss 7, p e0253139 (2021)
PloS one, vol 16, iss 7
PLoS ONE, Vol 16, Iss 7, p e0253139 (2021)
Keratinocyte migration into skin wounds is the step of the healing process that correlates with the wound closure rate. Keratinocyte migration, and wound epithelialization are decreased when beta 2-adrenergic receptors (B2AR) are activated by 1 μM e
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 4, p e0249344 (2021)
PLoS ONE, Vol 16, Iss 4, p e0249344 (2021)
Purpose To examine the effect of prolactin (PRL) on human corneal stromal fibroblasts (CSFs), derived from healthy individuals and from keratoconus (KC) patients, in vitro, specifically assessing physiological and elevated PRL concentrations as appar
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0246375 (2021)
PLoS ONE, Vol 16, Iss 2, p e0246375 (2021)
Prostaglandin E2(PGE2)-induced coughsin vivoand vagal nerve depolarizationin vitroare inhibited by systemic and local administration of prostaglandin EP3 receptor (L-798106) and TRPV1 antagonists (JNJ 17203212). These results indicate a modulating ef
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 1, p e0245342 (2021)
PLoS ONE, Vol 16, Iss 1, p e0245342 (2021)
Purpose To analyze the short-term therapeutic efficacy of intravitreal injection of bevacizumab (IVB) for chronic central serous chorioretinopathy (CSC) according to the presence of choroidal neovascularization (CNV) using optical coherence tomograph
Autor:
Hiroshi Yaginuma, Taku Tsunekawa, Keigo Taki, Takeshi Onoue, Runan Sun, Yoshihiro Ito, Shintaro Iwama, Tomoko Kobayashi, Ryoichi Banno, Hiroshi Arima, Daisuke Sakano, Daisuke Hagiwara, Hiroshi Takagi, Akira Mizoguchi, Shoen Kume, Tomonori Hirose, Hidetaka Suga, Mariko Sugiyama
Publikováno v:
PLoS ONE, Vol 16, Iss 3, p e0248065 (2021)
PLoS ONE
PLoS ONE
Excessive sodium salt (NaCl) or fat intake is associated with a variety of increased health risks. However, whether excessive NaCl intake accompanied by a high-fat diet (HFD) affects glucose metabolism has not been elucidated. In this study, C57BL/6J
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0242897 (2021)
PLoS ONE, Vol 16, Iss 2, p e0242897 (2021)
Circadian rhythms are entrained by light and influenced by non-photic stimuli, such as feeding. The activity preceding scheduled mealtimes, food anticipatory activity (FAA), is elicited in rodents fed a limited amount at scheduled times. FAA is thoug
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 9, p e0238208 (2020)
PLoS ONE, Vol 15, Iss 9, p e0238208 (2020)
IntroductionPeripheral nerve injury (PNI) often leads to significant functional loss in patients and poses a challenge to physicians since treatment options for improving functional outcomes are limited. Recent studies suggest that erythropoietin and
Autor:
Germaine Boucher, Rachel J. Church, John M. Kreeger, Paul B. Watkins, Shelli J. Schomaker, J. Scott Eaddy, Jiri Aubrecht
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 10, p e0240562 (2020)
PLoS ONE, Vol 15, Iss 10, p e0240562 (2020)
Glutamate dehydrogenase (GLDH) is a liver-specific biomarker of hepatocellular damage currently undergoing qualification as a drug development tool. Since GLDH is located within the mitochondrial matrix, it has been hypothesized that it might also be
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0246161 (2021)
PLoS ONE, Vol 16, Iss 2, p e0246161 (2021)
Ursodeoxycholic acid (commercially available as ursodiol) is a naturally occurring bile acid that is used to treat a variety of hepatic and gastrointestinal diseases. Ursodiol can modulate bile acid pools, which have the potential to alter the gut mi
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 5, p e0232353 (2020)
PLoS ONE, Vol 15, Iss 5, p e0232353 (2020)
Importance Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness with several intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents available for its management such as aflibercept, bevacizumab, and ran